UK sets out world‑leading pathway for space‑manufactured drugs 

Patients could benefit from more effective, higher quality and longer lasting medicines as the UK sets out a clearer route to bring drugs manufactured in space safely to market.

ESA astronaut Samantha Cristoforetti working on pharmaceutical research on the International Space Station. Credit: NASA

The unique environment of microgravity, impossible to replicate on Earth, can improve how biologic drugs form, behave and work within the human body and have the potential to improve outcomes for people with cancer, rare diseases and other conditions by enhancing the quality, stability and performance of complex medicines.  

To help turn these advances into real world treatments, UK companies developing medicines in space will now benefit from a coordinated package of measures announced today to support the rapid growth of in-orbit manufacturing.  The measures will provide industry with greater regulatory clarity and a clearer pathway from research in orbit to patient access on Earth. As set out in the UK Government’s £2 billion Life Sciences Sector Plan, these innovations could expand treatment options and improve outcomes across the health system. 

Led by the UK Space Agency, with support from the Medicines and Healthcare products Regulatory Agency (MHRA), the Regulatory Innovation Office (RIO) within the Department for Science, Innovation and Technology (DSIT) and the Civil Aviation Authority (CAA), the package includes regulatory guidance, case studies, a regulatory sandbox and strengthened supply-chain engagement. By providing this clarity now, the UK is helping industry bring space-made medicines closer to patients.

The announcement came on the second day of Space-Comm Expo, at ExCeL London, one of Europe’s biggest space industry events.

The UK is taking medical breakthroughs from orbit to patient – tackling the practical barriers that have held back commercial in-orbit manufacturing, from regulatory uncertainty to supply chain gaps.